PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2026 results: revenue $44.8 million, net income net loss of $3.8 million, EPS $0.07 per basic and diluted share. Guidance raised.
“consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the first quarter ended March 31, 2026 , total revenue was $44.8 million, of which $42.0 million was net product revenue and $2.8 million was royalty revenue. This compares to total revenue of $46.0 million in the first quarter of 2025 , of which”
Governance Changes
PUMA BIOTECHNOLOGY, INC.: Amended and restated bylaws primarily to align with updates to Delaware law, with conforming changes (effective 2025-06-19).
“On June 19, 2025, the Board of Directors of Puma Biotechnology, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Fourth Amended and Restated Bylaws (as so amended, the “Amended Bylaws”) primarily to revise provisions in order to be more in line with certain updates to Delaware law.”
Jeff J. Ludwig was terminated as Chief Commercial Officer at PUMA BIOTECHNOLOGY, INC..
“On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.”
Earnings Releases
PUMA BIOTECHNOLOGY, INC. reported the first quarter ended March 31, 2024 results: revenue $43.8 million, net income net loss of $4.8 million, EPS $0.10 per basic and diluted share.
“sales of NERLYNX, Puma’s first commercial product, license revenue from Puma’s sub-licensees and royalty revenue. For the first quarter ended March 31, 2024, total revenue was $43.8 million, of which $40.3 million was net product revenue and $3.5 million was royalty revenue. This compares to total revenue of $52.8 million in the first quarter of 2023, of which $46.8”
Earnings Releases
PUMA BIOTECHNOLOGY, INC. reported financial results for fourth quarter and year ended December 31, 2023.
“On February 29, 2024, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.